drugset / Trial / NCT07149857
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
NaParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate how well (efficacy) cilta-cel works when given with a fludarabine-free lymphodepletion regimen (a process of reducing the number of lymphocytes, a type of white blood cell in the body, typically through chemotherapy), or an alternative administration of cilta-cel infusion following a cyclophosphamide and fludarabine lymphodepletion regimen.
Timeline
- Start
- 2025-10-03
- Primary completion
- 2028-04-12
- Completion
- 2029-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ciltacabtagene autoleucel | Cell therapy | — | Intravenous |
| Background | Bortezomib | Small molecule | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Daratumumab | Monoclonal antibody | — | — |
| Background | Dexamethasone | Small molecule | — | — |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Lenalidomide | Other / unclassified | — | — |